A new experimental drug could be successful in killing only the malignant B lymphocytes, which cause chronic lymphocytic leukemia (CLL).
Available leukemia drugs do not stop with the cancerous cells alone, but go on to destroy T lymphocytes too. A lymphocyte is a type of white blood cell in the vertebrate immune system. Small lymphocytes consist of T cells and B cells. T cells (Thymus cells) and B cells (bone cells) are the major cellular components of the adaptive immune response.
When CLL treatment destroys T lymphocytes along with the cancerous B lymphocytes, patients become highly susceptible to life-threatening infections.
"A drug that kills malignant B lymphocytes and spares T lymphocytes could dramatically improve outcomes for CLL patients," says study leader Dr. John C. Byrd, director, division of hematology and professor of medicine, of medicinal chemistry and of veterinary biosciences at the OSUCCC — James.
"Our collective results indicate that PCI-32765 is an outstanding candidate for further development as a therapeutic for CLL," says study co-director Dr. Amy J. Johnson, assistant professor of hematology and medicinal chemistry, and a CLL researcher with the OSUCCC-James.
The research by Byrd, Johnson and a group of colleagues used CLL cells from ten patients. It had several key findings related to PCI-32765:
The agent specifically targets an important signaling molecule called Bruton's tyrosine kinase, which is overexpressed in CLL cells and absent in T cells.
The agent inhibits the proliferation of CLL cells in laboratory culture and promotes their death by self-destruction (apoptosis).
It blocks survival signals from cells in the surrounding microenvironment, including soluble factors such as IL-6, IL-4, and TNF-á, and stromal-cell contact.